Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DeLauro wants FDA approvals list

This article was originally published in The Tan Sheet

Executive Summary

Concerned that commercial and political interests "permeated the culture" of FDA and led to the approval of unsafe or ineffective products, Rep. Rosa DeLauro, D-Conn., requests the agency list all drugs, devices and biologics it approved or cleared in the final three months of the Bush administration. The chairwoman of the Appropriations subcommittee with FDA oversight also asks acting FDA Commissioner Frank M. Torti in a Feb. 12 letter about agency decisions about the generally recognized as safe status for food products made between November 2008 and January 2009. FDA has until Feb. 26 to respond to DeLauro's request, which follows a January letter from agency scientists that "corrupt" FDA managers pushed approval of questionable products (1"The Tan Sheet" Jan. 19, 2009, p. 16)
Advertisement

Related Content

DeLauro Adds FDA Scientists’ Complaint To Her List Of Agency Problems
DeLauro Adds FDA Scientists’ Complaint To Her List Of Agency Problems

Topics

Advertisement
UsernamePublicRestriction

Register

PS102604

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel